Status:
RECRUITING
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
Lead Sponsor:
University of Miami
Conditions:
Venous Thromboembolism
Eligibility:
All Genders
19+ years
Phase:
PHASE2
Brief Summary
This research study is attempting to answer the question of whether 81 mg aspirin once daily is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint replacement surger...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- \> 18 years of age
- Planning to undergo a primary total hip or knee arthroplasty
- Exclusion Criteria:
- High risk patients for VTE as defined by:
- History of venous thromboembolism
- Active malignancy
- Known pro thrombotic condition
- BMI \> 40
- Patients requiring anticoagulation for pre-existing conditions
- Patients with the contraindication for use of aspirin or nonsteroidal antiinflammatory drugs for reasons such as peptic ulcer disease, intolerance, others.
- Patients not fluent in the language of the informed consent form
- Prisoners
- Pregnancy
- Reported to have mental illness or belonging to a vulnerable population
Exclusion
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
5478 Patients enrolled
Trial Details
Trial ID
NCT04295486
Start Date
March 1 2021
End Date
March 1 2026
Last Update
September 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Miami Hospital
Miami, Florida, United States, 33136